In our study, GM-CSF was specifically selected as the ‘proof-of-concept’ immunomodulatory drug payload as it is activates maturation of antigen-presenting cell populations (macrophages and dendritic cells) in the setting of increased tumor antigen availability (both of which are present in the immediate post-ablation zone) [27, 40]. This evidence concerns the gene CSF2 and neoplasm.